Neither TAVR nor open heart surgery is categorically better for every person with severe aortic stenosis. The answer depends on your age, your surgical risk profile, the anatomy of your aortic valve, and how many years of valve life you need. For patients over 80 or those with serious medical conditions that make surgery dangerous, TAVR delivers comparable survival with a much less invasive procedure. For younger patients expected to live decades, surgical valve replacement still has advantages, particularly because a second procedure down the road is simpler to manage after surgery than after TAVR. The gap between the two has narrowed considerably over the past decade, though, and the real question is less about which procedure is universally superior and more about which one fits your situation.
How Outcomes Compare Across Risk Levels
Clinical trials have tested TAVR against surgical aortic valve replacement (SAVR) in patients spanning the full range of surgical risk, and the results shift depending on how sick or fragile the patient is. In high-risk patients, five-year data show similar rates of death and stroke between the two procedures.1PubMed. At 5 years, transcatheter aortic valve replacement had similar rates of mortality and stroke as surgical aortic valve replacement in high-risk patients That finding was a landmark because TAVR was originally developed for patients who could not survive open heart surgery at all, and showing parity in high-risk patients cemented its role as a genuine alternative rather than a last resort.
In intermediate-risk patients, a large randomized trial found TAVR noninferior to surgery at two years. The composite outcome of death or disabling stroke occurred in roughly one in eight patients regardless of which procedure they received.2PubMed. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients The procedures were not identical in their complication profiles, though. Surgery carried higher rates of kidney injury, irregular heart rhythms (atrial fibrillation), and blood transfusions, while TAVR had more residual valve leakage and a higher need for permanent pacemaker implantation.2PubMed. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
The low-risk population is where the conversation gets most interesting. A 2025 meta-analysis pooling six randomized trials and over 5,300 patients found that TAVR was associated with a 20% reduction in the risk of death and a 19% reduction in the combined risk of death or disabling stroke at five years compared with surgery.3PubMed. Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials That sounds like a clear win for TAVR, but the picture becomes more complicated at longer follow-up. Six-year data from the Evolut Low Risk trial showed no significant difference in the combined rate of death or disabling stroke between TAVR and surgery. At six and seven years, however, the TAVR group had a higher rate of reintervention, driven by increasing aortic valve leakage over time.4PubMed. Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis This tension between good medium-term survival and potential long-term complications is the core of the TAVR-versus-surgery debate for younger, healthier patients.
Recovery and Short-Term Complications
The immediate experience of the two procedures is dramatically different. Open heart surgery requires general anesthesia, a sternotomy (splitting the breastbone), and time on a heart-lung bypass machine. Hospital stays typically last a week or more, and full recovery often takes two to three months. TAVR is done through a catheter inserted into the femoral artery in the groin, usually under conscious sedation. Many TAVR patients go home within a day or two, and some walk the same afternoon.
That difference in invasiveness shows up in complication data. In the PARTNER I trial, surgical patients had significantly higher rates of major bleeding within the first 30 days, with roughly one in four surgical patients experiencing a major bleed compared to about one in nine for TAVR via the femoral approach. Surgery also required far more blood transfusions.5PubMed. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial
There is also evidence that TAVR is gentler on the brain in the short term. A prospective study comparing TAVR to minimally invasive surgical valve replacement found that surgical patients experienced a measurable dip in cognitive function in the early days after the procedure, while TAVR patients did not. By six months, the surgical group had recovered to baseline, so the effect appears temporary, but it matters for older patients where even brief cognitive disruption can have cascading effects on independence.6PubMed Central. Cognitive and functional status after transcatheter and mini-aortic valve replacement: a prospective cohort study
Stroke Risk Is Closer Than You Might Expect
Many patients assume TAVR carries a higher stroke risk because threading a catheter through the aorta could dislodge debris. The evidence does not support that assumption. A large meta-analysis of seven randomized trials including nearly 7,800 patients found no meaningful difference in stroke rates between TAVR and surgery over long-term follow-up, regardless of whether patients were high-risk, intermediate-risk, or low-risk.7Journal of the Society for Cardiovascular Angiography & Interventions. Long-Term Outcomes of Transcatheter vs Surgical Aortic Valve Replacement: A Meta-Analysis of Randomized Trials
Looking at the timing of strokes, the pattern differs. Stroke risk after surgery peaks within the first day after the procedure, whereas after TAVR the early risk is lower and declines from there. Once you get past the first week, both groups experience the same low background stroke rate of about 1.3 to 1.4 strokes per 100 patient-years.8Journal of the American College of Cardiology. Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial Surgery did have a higher rate of major stroke in the first 30 days in that analysis, which likely reflects the trauma of the bypass machine and the operation itself.
The Valve Leak Problem
One area where TAVR consistently fares worse is paravalvular leak, the leaking of blood around the edges of the replacement valve rather than through it. This happens because a TAVR valve is crimped onto a catheter and expanded inside the old valve without the surgeon being able to sew it precisely into place. Even mild leak matters. A meta-analysis of individual patient data found that any degree of paravalvular leak after TAVR was associated with about a 50% higher risk of death over time.9PubMed Central. Impact of Paravalvular Leak on Outcomes After Transcatheter Aortic Valve Implantation: Meta-Analysis of Kaplan-Meier-derived Individual Patient Data
A large Japanese registry that followed TAVR patients for up to nine years found that about a third of patients had mild paravalvular leak, and those patients had significantly higher long-term mortality and valve failure compared with patients who had no or only trace leakage.10PubMed. Long-Term Impact of Mild Paravalvular Regurgitation After Transcatheter Aortic Valve Replacement: The OCEAN-TAVI Registry Newer-generation TAVR valves have improved on this front with better sealing skirts, but paravalvular leak remains more common after TAVR than after surgery, where the surgeon can sew the valve directly to the tissue and visually confirm the seal.
How Long the Valves Last
This is probably the single most important unanswered question in the field. TAVR has only been widely used since around 2010, so truly long-term data, spanning 15 or 20 years, simply does not exist yet. Both TAVR and surgical bioprosthetic valves are made from similar animal tissue (usually cow or pig pericardium), so in theory they should degrade at comparable rates. The available data at five to ten years actually suggests that structural valve deterioration may be slightly lower after TAVR than after surgery, though the overall rate of valve failure requiring reintervention is similar between the two approaches.11PubMed Central. Transcatheter aortic valve durability: a contemporary clinical review In one comparative analysis, the rate of structural deterioration was 24% after surgery versus under 5% after TAVR, though the rate of complete valve failure was the same.12PubMed. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk
The concern is not whether the first TAVR valve will last, but what happens when it eventually fails. A failed surgical valve can be replaced with another surgical valve or treated with a valve-in-valve TAVR procedure, which fits a new transcatheter valve inside the old one. But when a TAVR valve fails, putting a second TAVR valve inside creates a nested set of metal frames that can obstruct the coronary arteries or leave too little room for the new valve to function well. Surgical explantation of a failed TAVR valve is possible but technically demanding and carries high reported rates of complications and death.13PubMed. Challenges and Future Directions in Redo Aortic Valve Reintervention After Transcatheter Aortic Valve Replacement Failure This “lifetime management” concern is the strongest argument for starting with surgery in younger patients who will almost certainly need at least one additional valve replacement during their lives.
Bicuspid Valves Are a Special Case
About 1 to 2% of people are born with a bicuspid aortic valve, meaning two leaflets instead of the usual three. This anatomy creates an asymmetric, often calcified opening that makes it harder for a TAVR valve to sit evenly. Most of the landmark TAVR trials excluded bicuspid patients, so the comparison data comes from registries and observational studies rather than randomized trials.
The results consistently favor surgery for this group. A national-level study of patients over 65 with bicuspid aortic stenosis found that after propensity matching, TAVR was associated with roughly double the mortality of surgery at three years. TAVR also carried a higher risk of heart failure readmission beyond the first year.14AATS Archives. Bicuspid Aortic Stenosis: National 3-Year Outcomes of TAVR versus SAVR A more recent study confirmed the trend, finding that at two years, TAVR patients with bicuspid valves had significantly higher rates of stroke and valve dysfunction compared to surgical patients.15PubMed Central. Surgical Versus Transcatheter Aortic Valve Replacement in Bicuspid Aortic Stenosis: 1-Year Clinical Outcomes in Patients Aged 65 Years and Older If you have a bicuspid valve, surgery is generally the preferred approach unless your surgical risk is very high.
What the Guidelines Actually Recommend
Both the American (ACC/AHA) and European (ESC/EACTS) guidelines use age and life expectancy as the primary sorting tools, though they draw the lines at slightly different places. The American guidelines recommend surgery for patients under 65 or those with a life expectancy over 20 years, and recommend TAVR for patients over 80 or those with a life expectancy under 10 years. The European guidelines set the surgery preference threshold at under 75 with low surgical risk, and the TAVR preference threshold at 75 and older.16European Heart Journal. ESC/EACTS vs. ACC/AHA Guidelines for the Management of Severe Aortic Stenosis
The big gray zone is between 65 and 80 (or 75, depending on which guidelines you follow). In this range, the decision is supposed to be made by a “heart team” that includes both an interventional cardiologist and a cardiac surgeon, weighing your specific anatomy, comorbidities, and preferences. The emphasis on lifetime management, meaning thinking ahead to what happens if and when the first valve fails, is growing in both sets of guidelines.17PubMed Central. Lifetime Management of Aortic Stenosis: Evolving Strategies and Personalized Decision-Making
Where You Get the Procedure Matters More Than You Think
Hospital experience with both procedures has a measurable effect on outcomes, and the relationship is not what you might expect. Hospitals that perform a high volume of both TAVR and surgical valve replacements have the lowest in-hospital mortality. Hospitals that are busy with TAVR but do very little surgery do not see the same benefit.18PubMed Central. Clinical Outcomes in Relation to Total Hospital Surgical and Transcatheter Aortic Valve Replacement Volumes
This finding has been confirmed from multiple angles. One study found that TAVR patients treated at hospitals with low surgical valve replacement volumes had a death-or-discharge-against-medical-advice rate of 6.4%, versus 4.0% at hospitals with high surgical volumes. After adjusting for patient characteristics, low surgical volume was independently associated with worse TAVR outcomes.19PubMed Central. Impact of surgical aortic valve and coronary intervention volume on transcatheter aortic valve replacement outcomes The likely explanation is that a hospital with a strong surgical program has the infrastructure, expertise, and team culture to manage complications when they arise during TAVR, including the rare cases that need emergency conversion to open surgery. This is a strong argument for choosing a center where both options are performed at high volume rather than a facility that specializes exclusively in one approach.20PubMed Central. Relationship Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes
Cost and Value
TAVR’s initial hospitalization costs are higher than surgery’s, mostly because the transcatheter valve device itself is expensive. One economic analysis estimated the upfront cost difference at about $11,000 per patient, with a projected lifetime difference of roughly $18,000. However, TAVR was projected to provide an additional 0.32 quality-adjusted life-years, yielding a cost-effectiveness ratio of about $55,000 per quality-adjusted life-year gained, which falls within the range generally considered acceptable in healthcare economics.21PubMed Central. Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement
The cost picture is shifting, though. A global systematic review found that TAVR was cost-effective in 14 out of 15 studies analyzed, with the only exception being a study conducted in a developing country where the device cost was prohibitive relative to local healthcare spending.22Canadian Journal of Cardiology. Global Cost-Effectiveness of Transcatheter vs Surgical Aortic Valve Replacement in Severe Aortic Stenosis: A Systematic Review and Meta-analysis As newer and cheaper TAVR devices enter the market, the cost gap is expected to narrow further.23PubMed Central. A Review of the Cost Effectiveness of Transcatheter Aortic Valve Replacement (TAVR) Versus Surgical Aortic Valve Replacement (SAVR) The shorter hospital stay and faster return to daily life with TAVR also create indirect savings that are harder to capture in clinical cost analyses but very real for patients and families.
What Patients Themselves Prefer
When researchers have directly asked patients about their preferences, the results reflect the complexity of the decision. A benefit-risk analysis study found that a majority of patients preferred TAVR, which makes intuitive sense given the less invasive recovery. But about 20% of patients preferred surgery even after learning about both options.24PubMed Central. Patient-centered benefit-risk analysis of transcatheter aortic valve replacement The reasons varied. Some valued the longer track record of surgical valves. Others felt more comfortable with a procedure where the surgeon could directly visualize and sew the valve. Some simply preferred the certainty of a known approach over a newer technology. That heterogeneity in preferences is itself a finding: there is no one-size-fits-all answer here, and the decision should involve a real conversation with your treatment team rather than a default to whichever procedure your hospital does more often.